Tatsis Ourania 4

What Happened

Ourania Tatsis, EVP and Chief Regulatory & Quality Officer at Vertex Pharmaceuticals (VRTX), received an award of 8,251 restricted stock units (RSUs) on 2026-07-21. The grant is reported at $0.00 per share (common for RSU awards); there was no cash purchase or sale in this transaction.

Key Details

• Transaction type: Award/Grant (code A) of 8,251 RSUs, reported acquisition price $0.00.
• Grant date: 2026-07-21; Form 4 filed 2026-07-23 (within the typical 2-business-day filing window).
• Vesting: These RSUs vest on 03/31/2030 (footnote F1).
• Shares owned after transaction: Not specified in the provided filing details.
• No 10b5-1, tax-withholding, or sale information disclosed in this record.

Context

RSUs are compensation awards that convert into company shares if and when they vest; they are common retention/compensation tools and do not represent an immediate buy or sell in the market. Because this is a grant (not a market purchase or sale), it signals compensation/retention action rather than an immediate view on the stock price.